<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="492">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 30, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364737</url>
  </required_header>
  <id_info>
    <org_study_id>2020-11467</org_study_id>
    <nct_id>NCT04364737</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients</brief_title>
  <official_title>Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of
      anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms
      requiring oxygen supplementation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 300 eligible subjects will be randomized in a 1:1 ratio to receive either
      convalescent plasma (CP) from people who have recovered from COVID-19 containing antibodies
      to SARS-CoV-2 or a placebo control, Lactated Ringer's Solution (LR) or saline solution (SS).
      Hospitalized COVID-19 patients aged ≥18 years of age with respiratory symptoms within 3 to 7
      days from the onset of illness OR within 3 days of hospitalization will be eligible to
      participate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects reporting each severity rating on WHO ordinal scale for clinical improvement</measure>
    <time_frame>14 days post randomization</time_frame>
    <description>No clinical or virological evidence of infection
Not hospitalized, no limitations on activities
Not hospitalized, limitation on activities
Hospitalized, not requiring supplemental oxygen
Hospitalized, requiring supplemental oxygen
Hospitalized, on non-invasive ventilation or high flow oxygen devices
Hospitalized, on invasive mechanical ventilation or ECMO
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects reporting each severity rating on WHO ordinal scale for clinical improvement</measure>
    <time_frame>28 days post randomization</time_frame>
    <description>No clinical or virological evidence of infection
Not hospitalized, no limitations on activities
Not hospitalized, limitation on activities
Hospitalized, not requiring supplemental oxygen
Hospitalized, requiring supplemental oxygen
Hospitalized, on non-invasive ventilation or high flow oxygen devices
Hospitalized, on invasive mechanical ventilation or ECMO
Death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison in Anti-SARS-CoV-2 antibody titers</measure>
    <time_frame>0, 1, 7, 14, 28, 90 days post randomization</time_frame>
    <description>Anti-SARS-CoV-2 titers (IgM, IgG, IgA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion positive in SARS-CoV-2 RNA</measure>
    <time_frame>0, 7, 14, 28 days post randomization</time_frame>
    <description>SARS-CoV-2 PCR in nasopharyngeal swabs</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>7, 14, 28 days post randomization</time_frame>
    <description>Rate of mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Rates of Intensive Care Unit admission</measure>
    <time_frame>7, 14, 28 days post randomization</time_frame>
    <description>Percentage of patients requiring Intensive Care Unit admission</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in lymphocyte</measure>
    <time_frame>0, 1, 3, 7, 14 days post randomization</time_frame>
    <description>Lymphocyte counts</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in neutrophils</measure>
    <time_frame>0, 1, 3, 7, 14 days post randomization</time_frame>
    <description>Neutrophil counts</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in D-dimer</measure>
    <time_frame>0, 1, 3, 7, 14 days post randomization</time_frame>
    <description>D-dimer level</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in fibrinogen</measure>
    <time_frame>0, 1, 3, 7, 14 days post randomization</time_frame>
    <description>Fibrinogen level</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in T lymphocyte subsets</measure>
    <time_frame>0, 7, 28 days post randomization</time_frame>
    <description>T cell subsets</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in B lymphocyte subsets</measure>
    <time_frame>0, 1, 3, 7, 14 days post randomization</time_frame>
    <description>B cell subsets</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19</condition>
  <condition>Coronavirus</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Convalescent donor plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactated ringer's solution or sterile saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent Plasma</intervention_name>
    <description>SARS-CoV-2 convalescent plasma (1-2 units; ~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate</description>
    <arm_group_label>Convalescent donor plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lactated ringer's solution or sterile saline</intervention_name>
    <description>Equivalent volume of Lactated ringer's or sterile saline solution will be administered to eligible candidate as a control group</description>
    <arm_group_label>Lactated ringer's solution or sterile saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years of age

          -  Hospitalized for COVID-19 respiratory symptoms

          -  Hospitalized for less than 72 hours OR within day 3 to 7 days from first signs of
             illness

          -  Laboratory confirmed COVID-19

          -  On supplemental oxygen, non-invasive ventilation or high-flow oxygen

          -  Patients may be on other randomized controlled trials of pharmaceuticals for COVID -19
             and patients who meet eligibility criteria will not be excluded on this basis.

        Exclusion Criteria:

          -  Receipt of pooled immunoglobulin in past 30 days

          -  Contraindication to transfusion or history of prior reactions to transfusion blood
             products

          -  Invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)

          -  Volume overload secondary to congestive heart failure or renal failure

          -  Intracranial bleed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liise-anne Pirofski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liise-anne Pirofski, MD</last_name>
    <phone>718-430-2940</phone>
    <email>l.pirofski@einsteinmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyunah Yoon, MD</last_name>
    <email>hyoon@montefiore.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mila Ortigoza, MD</last_name>
      <phone>803-240-8328</phone>
      <email>Mila.Ortigoza@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Mila Ortigoza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Liise-anne Pirofski</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

